Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside"

Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Epub 2019 Mar 13.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Oncogene Proteins, Fusion / antagonists & inhibitors
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, trkA / antagonists & inhibitors
  • Receptor, trkA / genetics*
  • Receptor, trkB / antagonists & inhibitors
  • Receptor, trkB / genetics*
  • Receptor, trkC / antagonists & inhibitors
  • Receptor, trkC / genetics*

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Receptor, trkA
  • Receptor, trkB
  • Receptor, trkC
  • larotrectinib